Metabolic Effects of Gastrectomy and Duodenal Bypass in Early Gastric Cancer Patients with T2DM: A Prospective Single-Center Cohort Study
Authors:
- Young Ki LeeYLYoung Ki Lee
- Eun Kyung LeeELEun Kyung Lee
- You Jin LeeYLYou Jin Lee
- Bang Wool EomBEBang Wool Eom
- Hong Man YoonHYHong Man Yoon
- Young-Il KimYKYoung-Il Kim
- Soo Jeong ChoSCSoo Jeong Cho
- Jong Yeul LeeJLJong Yeul Lee
- Chan Gyoo KimCKChan Gyoo Kim
- Sun-Young KongSKSun-Young Kong
- Min Kyong YooMYMin Kyong Yoo
- Yul HwangboYHYul Hwangbo
Open Access
- 4 September 2021
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (17) , 4008
Abstract
We evaluated the metabolic effects of gastrectomies and endoscopic submucosal dissections (ESDs) in early gastric cancer (EGC) patients with type 2 diabetes mellitus (T2DM). Forty-one EGC patients with T2DM undergoing gastrectomy or ESD were prospectively evaluated. Metabolic parameters in the patients who underwent gastrectomy with and without a duodenal bypass (groups 1 and 2, n = 24 and n = 5, respectively) were compared with those in patients who underwent ESD (control, n = 12). After 1 year, the proportions of improved/equivocal/worsened glycemic control were 62.5%/29.2%/8.3% in group 1, 40.0%/60.0%/0.0% in group 2, and 16.7%/50.0%/33.3% in the controls, respectively (p = 0.046). The multivariable ordered logistic regression analysis results showed that both groups had better 1-year glycemic control. Groups 1 and 2 showed a significant reduction in postprandial glucose (−97.9 and −67.8 mg/dL), body mass index (−2.1 and −2.3 kg/m2), and glycosylated hemoglobin (group 1 only, −0.5% point) (all p < 0.05). Furthermore, improvements in group 1 were more prominent when preoperative leptin levels were high (p for interaction < 0.05). Metabolic improvements in both groups were also observed for insulin resistance, leptin, plasminogen activator inhibitor-1, and resistin. Gastrectomy improved glycemic control and various metabolic parameters in EGC patients with T2DM. Patients with high leptin levels may experience greater metabolic benefits from gastrectomy with duodenal bypass.Keywords
Funding Information
- National Cancer Center (1210552-3, 1510740-1, 1410650-1)
This publication has 37 references indexed in Scilit:
- Improvement of diabetes and hypertension after gastrectomy: A nationwide cohort studyWorld Journal of Gastroenterology, 2015
- Leptin Mediates the Increase in Blood Pressure Associated with ObesityCell, 2014
- Comparison of different gastric bypass procedures in gastric carcinoma patients with type 2 diabetes mellitusWorld Journal of Gastroenterology, 2014
- Identifying important comorbidity among cancer populations using administrative data: Prevalence and impact on survivalAsia-Pacific Journal of Clinical Oncology, 2013
- Annual Report to the Nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancerCancer, 2013
- Roux-en-Y Gastric Bypass vs Intensive Medical Management for the Control of Type 2 Diabetes, Hypertension, and HyperlipidemiaJAMA, 2013
- Does Roux-en-Y gastrectomy for gastric cancer influence glucose homeostasis in lean patients?Surgical Endoscopy, 2013
- Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with DiabetesNew England Journal of Medicine, 2012
- Outcome after gastrectomy in gastric cancer patients with type 2 diabetesWorld Journal of Gastroenterology, 2012
- Cytokine and Cytokine-Like Inflammation Markers, Endothelial Dysfunction, and Imbalanced Coagulation in Development of Diabetes and Its ComplicationsThe Journal of Clinical Endocrinology & Metabolism, 2009